Vivacta Bio Raises Over $50 Million Across Series A and A+ to Advance…

Team S · 2026-04-29T14:47:09.000Z

Shanghai-based biotech innovator Vivacta Bio has completed Series A and Series A+ financing totaling over $50 million, strengthening its position in the fast-growing cell therapy market. The funding round reflects rising investor confidence in next-generation in vivo CAR-T therapies, a breakthrough area aiming to simplify and scale cancer and autoimmune treatments. The two rounds were led separately by Loyal Valley Capital and Decheng Capital, with participation from major healthcare investors including OrbiMed, Hankang Capital, Eisai Innovation Inc., C&D Emerging Industry Equity Investment, along with existing backers Qiming Venture Partners, Beijing Shunxi, and Apricot Capital. The diverse syndicate combines global biotech expertise with strategic growth capital. Founded by Dr. Liu Yarong, Vivacta Bio is focused on pioneering in vivo CAR-T cell therapy, an emerging approach that engineers immune cells directly inside the body rather than through complex ex vivo manufacturing. This model could significantly reduce treatment cost, improve access, and shorten time-to-therapy for patients. The company’s lead program GT801 has shown promising early safety and efficacy signals in studies involving hematological malignancies and autoimmune diseases. Initial human data was also presented at the American Society of Hematology (ASH) Annual Meeting 2025, increasing visibility for the platform among global clinicians and investors. Fresh capital will be used to accelerate clinical trials for GT801, support regulatory submissions, expand research capabilities, and drive global commercialization efforts. As biotech investors increasingly target transformative immune therapies, Vivacta Bio enters a critical scale-up phase. Vivacta’s latest raise also highlights continued momentum in China’s biotech ecosystem, where startups are advancing globally competitive innovation across oncology, autoimmune disease, and advanced therapeutics.

Member Login Get Access

Vivacta Bio Raises Over $50 Million Across Series A and A+ to Advance… | Newnex